Yarrow Bioscience, Inc. YARW
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- -38.17%
- 1 year
- +0.73%
- Open
- 20.65
- Prev close
- 19.90
- Mkt cap
- 166.83M
- Vol
- 417.72K
- Avg vol
- 114.38K
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 16.62
- High
- 20.65
News
20 hours ago businesswire.com
Yarrow Bioscience Announces Participation in November Investor Events
NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for…
1 month ago defenseworld.net
Contrasting Yarrow Bioscience (NASDAQ:YARW) and Atara Biotherapeutics (NASDAQ:ATRA)
Yarrow Bioscience (NASDAQ: YARW - Get Free Report) and Atara Biotherapeutics (NASDAQ: ATRA - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will…
1 month ago businesswire.com
Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for…
1 month ago businesswire.com
Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering
NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for…
-
1 month ago benzinga.com
Yarrow Bioscience Launches Underwritten Public Offering To Fund Pipeline Development And Corporate Operations; No Terms Disclosed
Yarrow Bioscience, Inc. ("Yarrow" or the "Company") (NASDAQ:YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today…
1 month ago businesswire.com
Yarrow Bioscience Announces Proposed Underwritten Public Offering
NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for…
-
2 months ago benzinga.com
Yarrow Bioscience Q2 EPS $(2.14) Misses $(0.22) Estimate
Yarrow Bioscience (NASDAQ:YARW) reported quarterly losses of $(2.14) per share which missed the analyst consensus estimate of $(0.22) by 872.73 percent.
2 months ago businesswire.com
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update
NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience reports second quarter 2026 financial results and provides a business update.
3 months ago benzinga.com
This Charles Schwab Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday
Wall Street analysts changed outlook on top names. For full changes, see our analyst ratings page. Analysts have mixed opinions on SCHW stock.
-
3 months ago benzinga.com
BTIG Initiates Coverage On Yarrow Bioscience with Buy Rating, Announces Price Target of $58
BTIG analyst Julian Harrison initiates coverage on Yarrow Bioscience (NASDAQ:YARW) with a Buy rating and announces Price Target of $58.
3 months ago businesswire.com
Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves' Disease and Thyroid Eye Disease
NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for…
3 months ago globenewswire.com
VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience
NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that its previously announced special cash dividend (the “Cash Dividend”),…
3 months ago globenewswire.com
VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience
NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that its Board of Directors has approved a reverse stock split of VYNE's…
3 months ago globenewswire.com
VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience
Aggregate cash dividend of an estimated $16.5 million, or an estimated $0.38 per share Aggregate cash dividend of an estimated $16.5 million, or an estimated $0.38 per share
6 months ago defenseworld.net
Short Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Decreases By 35.7%
VYNE Therapeutics Inc. (NASDAQ: VYNE - Get Free Report) was the recipient of a significant decrease in short interest in the month of March. As of March 31st, there was short interest totaling…
7 months ago defenseworld.net
Contrasting Vivani Medical (NASDAQ:VANI) & VYNE Therapeutics (NASDAQ:VYNE)
VYNE Therapeutics (NASDAQ: VYNE - Get Free Report) and Vivani Medical (NASDAQ: VANI - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two…
7 months ago defenseworld.net
VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Down 61.3% in February
VYNE Therapeutics Inc. (NASDAQ: VYNE - Get Free Report) was the target of a large drop in short interest in February. As of February 27th, there was short interest totaling 212,702 shares, a drop of…
10 months ago prnewswire.com
Shareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
MILWAUKEE , Dec. 18, 2025 /PRNewswire/ -- The Ademi Firm is investigating VYNE (Nasdaq: VYNE) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction…
10 months ago prnewswire.com
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE)
NEW YORK , Dec. 17, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is…
10 months ago seekingalpha.com
VYNE Therapeutics Inc. (VYNE) Yarrow Bioscience, Inc. - M&A Call Prepared Remarks Transcript
VYNE Therapeutics Inc. (VYNE) Yarrow Bioscience, Inc. - M&A Call Prepared Remarks Transcript
10 months ago businesswire.com
VYNE Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of VYNE Therapeutics Inc. is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of VYNE Therapeutics Inc. (NASDAQ: VYNE) and Yarrow Bioscience, Inc. is fair to VYNE…
10 months ago globenewswire.com
VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement
NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE”) and Yarrow Bioscience, Inc. (“Yarrow”) today announced that they have entered into a definitive merger…
12 months ago zacks.com
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates
VYNE Therapeutics Inc. (VYNE) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.29 per share a year ago.
12 months ago globenewswire.com
VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update
Company is progressing its previously initiated strategic review evaluating a range of options to maximize shareholder value, including assessment of internal pipeline opportunities and broader…
1 year ago defenseworld.net
Savara (NASDAQ:SVRA) vs. VYNE Therapeutics (NASDAQ:VYNE) Critical Comparison
Savara (NASDAQ: SVRA - Get Free Report) and VYNE Therapeutics (NASDAQ: VYNE - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two…